Efficacy of neuroradiological imaging, neurological examination, and symptom status in follow-up assessment of patients with high-grade gliomas

Journal of Neurosurgery

Volumn 93, Issue 2, 2000, Pages 201-207

  Galanis, Evanthia ^a   Buckner, Jan C ^b   Novotny, Paul ^b   Morton, Roscoe F ^b   McGinnis, William L ^b   Dinapoli, Robert ^b   Schomberg, Paula ^b   O'Fallon, Judith R ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

Clinical deterioration; Computerized tomography; Glioma; Magnetic resonance imaging; Tumor recurrence

Indexed keywords

ADULT; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; GLIOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC EXAMINATION; NEURORADIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SURVIVAL TIME; SYMPTOMATOLOGY; TUMOR GROWTH; TUMOR RECURRENCE;

EID: 0033859041     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.2000.93.2.0201     Document Type: Article

References (17)

1. Breiman L, Friedman JH, Olshen RA, et al: Classification and Regression Trees. Belmont, CA: Wadsworth, 1984
2. Buckner JC, Schomberg PJ, McGinnis WL, et al: Phase III study of radiation therapy (RT) plus BCNU with or without recombinant interferon alpha (IFN) in high-grade glioma: an NCCTG study. Proc Am Soc Clin Oncol 16:385a, 1997 (Abstract)
3. Cockrell JR, Folstein MF: Mini-Mental State Examination (MMSE). Psychopharmacol Bull 24:689-692, 1988
4. Cox DR: Regression models and life tables. J R Stat Soc B 34: 187-202, 1972
5. Del Turco MR, Palli D, Cariddi A, et al: Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. JAMA 271:1593-1597, 1994
6. Friedman HS, Kun LE: More on surveillance of children with medulloblastoma. N Engl J Med 332:191, 1995 (Letter)
7. The GIVIO Investigators: Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. JAMA 271: 1587-1592, 1994
8. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
9. Kattlove H, Liberati A, Keeler E, et al: Benefits and costs of screening and treatment for early breast cancer. Development of a basic benefit package. JAMA 273:142-148, 1995
10. LeBlanc M, Crowley J: Relative risk trees for censored survival data. Biometrics 48:411-425, 1992
11. Lindsey KL: Surveillance scanning of children with medulloblastoma. N Engl J Med 331:483, 1994 (Letter)
12. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
13. Rajkumar SV, Buckner JC, Schomberg PJ, et al: Phase I evaluation of preirradiation chemotherapy with carmustine and cisplatin and accelerated radiation therapy in patients with high-grade gliomas. Neurosurgery 44:67-73, 1999
14. Rajkumar SV, Buckner JC, Schomberg PJ, et al: Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma. Int J Radiat Oncol Biol Phys 40:297-302, 1998
15. Torres CF, Rebsamen S, Silber JH, et al: Surveillance scanning of children with medulloblastoma. N Engl J Med 330: 892-895, 1994
16. Weiss M, Loprinzi CL, Creagan ET, et al: Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA 274:1703-1705, 1995
17. Zubrod CG, Schneiderman M, Frei E, et al: Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chron Dis 11:7-33, 1960